2021
An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer
KISS, David, Táňa MACHÁČKOVÁ, Kamila SOUČKOVÁ, Pavel FABIAN, Iveta KŘEPELKOVÁ et. al.Základní údaje
Originální název
An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer
Autoři
KISS, David (203 Česká republika), Táňa MACHÁČKOVÁ (203 Česká republika, domácí), Kamila SOUČKOVÁ (203 Česká republika, domácí), Pavel FABIAN (203 Česká republika), Iveta KŘEPELKOVÁ (203 Česká republika), M. SVOBODA a Igor KISS (203 Česká republika, garant, domácí)
Vydání
In vivo, ATHENS, Greece : International Institute of Anticancer Research, 2021, 0258-851X
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30204 Oncology
Stát vydavatele
Řecko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 2.406
Kód RIV
RIV/00216224:14740/21:00120233
Organizační jednotka
Středoevropský technologický institut
UT WoS
000691746000013
Klíčová slova anglicky
Bevacizumab; metastatic colorectal cancer; microRNA; progression-free survival; predictive biomarker; validation
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 15. 10. 2024 14:27, Ing. Martina Blahová
Anotace
V originále
Background/Aim: The monoclonal antibody bevacizumab is a standard drug used in combination with oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) based chemotherapy in the first or second-line treatment of metastatic colorectal cancer (mCRC). Our previous study identified and subsequently validated 4 microRNAs in a small group of patients as predictors of the therapeutic response to bevacizumab combined with chemotherapy. The aim of this follow-up study is to confirm the predictive ability of these tissue miRNAs in a larger independent cohort of mCRC patients. Patients and Methods: The retrospective study included 92 patients with generalized-radically inoperable tumors treated with the combined therapy of bevacizumab/FOLFOX in a standard regimen. Results: Expression levels of candidate miRNA biomarkers (miR-92b3p, miR-3156-5p, miR-10a-5p and miR-125a-5p) were determined in tumor tissue specimens and statistically evaluated. MiR-92b-3p and miR-125a-5p were confirmed to be associated with radiological response according to RECIST criteria (p=0.005 and 0.05, respectively) and to be up-regulated in responders to bevacizumab/FOLFOX therapy. Higher levels of miR-92b-3p were also significantly associated with extended progression-free survival
Návaznosti
NU20-03-00127, projekt VaV |
| ||
90091, velká výzkumná infrastruktura |
|